Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research started coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $40.00 price objective on the stock.

Several other research firms have also recently weighed in on CNTA. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 price target on the stock. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. B. Riley Financial lifted their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Finally, Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $38.64.

Centessa Pharmaceuticals Stock Up 4.0%

CNTA opened at $26.52 on Tuesday. The firm has a market capitalization of $3.87 billion, a P/E ratio of -14.49 and a beta of 1.56. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $30.58. The company has a fifty day moving average price of $24.25 and a 200-day moving average price of $23.47. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares in the company, valued at $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This represents a 5.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 49,961 shares of company stock valued at $1,304,878. Company insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its stake in Centessa Pharmaceuticals by 34.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 12.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after purchasing an additional 1,246,741 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 24.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock worth $134,480,000 after purchasing an additional 1,045,750 shares during the last quarter. Siren L.L.C. increased its stake in shares of Centessa Pharmaceuticals by 24.8% in the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after buying an additional 800,000 shares during the period. Finally, Commodore Capital LP increased its stake in shares of Centessa Pharmaceuticals by 39.3% in the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after buying an additional 930,711 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.